{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:36Z","timestamp":1786984296987,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003348","name":"Fukuda Foundation for Medical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008731","name":"Nakatomi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.amjcard.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T15:56:54Z","timestamp":1776787014000},"page":"113-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Hypertensive Heart Disease and HFpEF: What We Have Learned in the Last Decade"],"prefix":"10.1016","volume":"270","author":[{"given":"Ryohei","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3574-9807","authenticated-orcid":false,"given":"Luiz Menezes","family":"Falc\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2026.04.006_bib0001","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41440-025-02312-x","article-title":"Hypertensive heart disease: is it really a pathology?","volume":"48","author":"Bellicini","year":"2025","journal-title":"Hypertens Res"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0002","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40256-024-00641-9","article-title":"Drug therapy for acute and chronic heart failure with preserved ejection fraction with hypertension: a state-of-the-art review","volume":"24","author":"Hiraiwa","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0003","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0004","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.repc.2025.02.007","article-title":"Primary heart failure with preserved ejection fraction: the intertwined pathophysiology and treatment of some of the most relevant phenotypes","volume":"44","author":"Ono","year":"2025","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0005","first-page":"25","article-title":"Hypertension and heart failure: from pathophysiology to treatment","author":"Gallo","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0006","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2017.04.012","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0007","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0008","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0009","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0011","article-title":"Sex differences in heart failure with preserved ejection fraction: from traditional risk factors to sex-specific risk factors","volume":"18","author":"Kaur","year":"2022","journal-title":"Womens Health (Lond)"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0012","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jacc.2019.12.049","article-title":"Menopause-related estrogen decrease and the pathogenesis of HFpEF: JACC review topic of the week","volume":"75","author":"Sabbatini","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0013","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/HCO.0b013e32834b7faf","article-title":"Why are women more likely than men to develop heart failure with preserved ejection fraction?","volume":"26","author":"Scantlebury","year":"2011","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0014","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13062-025-00618-x","article-title":"The role of estrogen in the sex difference for the risk factors of heart failure with preserved ejection fraction","volume":"20","author":"Du","year":"2025","journal-title":"Biol Direct"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0015","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0016","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"Levy","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0017","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1002\/ejhf.945","article-title":"A comprehensive population-based characterization of heart failure with mid-range ejection fraction","volume":"19","author":"Koh","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0018","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0019","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0021","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/HYPERTENSIONAHA.120.16483","article-title":"Worldwide trends in prevalence, mortality, and disability-adjusted life years for hypertensive heart disease from 1990 to 2017","volume":"77","author":"Dai","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0022","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1205475","article-title":"Hypertensive heart disease: risk factors, complications and mechanisms","volume":"10","author":"Masenga","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0024","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002763","article-title":"Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction","volume":"9","author":"Santos","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0025","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.echo.2025.03.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by Echocardiography and for heart failure with preserved ejection fraction diagnosis: an update from the American Society of Echocardiography","volume":"38","author":"Nagueh","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0026","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3390\/cells14141117","article-title":"The role of inflammation in the pathophysiology of heart failure","volume":"14","author":"Amara","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0027","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/01.CIR.102.4.470","article-title":"Left ventricular hypertrophy: pathogenesis, detection, and prognosis","volume":"102","author":"Lorell","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0028","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/eurheartj\/ehaf524","article-title":"Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment","volume":"47","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0029","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ejhf.2843","article-title":"Ventricular stiffening and chamber contracture in heart failure with higher ejection fraction","volume":"25","author":"Popovic","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0031","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cells9010242","article-title":"Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding","volume":"9","author":"Simmonds","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0032","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11906-020-1017-9","article-title":"Pathophysiology of hypertensive heart disease: beyond left ventricular hypertrophy","volume":"22","author":"Nwabuo","year":"2020","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0033","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.amjcard.2025.08.035","article-title":"Coronary artery disease in heart failure with preserved ejection fraction","volume":"258","author":"Ono","year":"2026","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0034","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10741-019-09855-5","article-title":"The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure","volume":"25","author":"Pugliese","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014669","article-title":"Predictors of mortality by sex and race in heart failure with preserved ejection fraction: ARIC Community surveillance study","volume":"9","author":"Sharma","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0036","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","article-title":"Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction","volume":"3","author":"Tsimploulis","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0037","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jacc.2016.07.754","article-title":"Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control","volume":"68","author":"McEvoy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0038","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2018.04.031","article-title":"Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction","volume":"263","author":"Tsujimoto","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0039","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ejhf.3108","article-title":"Blood pressure levels and adverse cardiovascular outcomes in heart failure: a systematic review and meta-analysis","volume":"26","author":"Seidu","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0040","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jchf.2019.05.015","article-title":"Health-related quality of life in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"7","author":"Chandra","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0041","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamacardio.2017.3983","article-title":"Association of serial Kansas City cardiomyopathy questionnaire assessments with death and hospitalization in patients with heart failure with preserved and reduced ejection fraction: a secondary analysis of 2 randomized clinical trials","volume":"2","author":"Pokharel","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0042","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ejhf.630","article-title":"Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"18","author":"Gorter","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0043","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0044","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ihj.2021.06.011","article-title":"Prognostic role of anemia in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"73","author":"Majmundar","year":"2021","journal-title":"Indian Heart J"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0045","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ehf2.14958","article-title":"Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction","volume":"12","author":"Xu","year":"2025","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0046","doi-asserted-by":"crossref","first-page":"e2330","DOI":"10.1097\/MD.0000000000002330","article-title":"Precipitating factors for acute heart failure hospitalization and long-term survival","volume":"94","author":"Berkovitch","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0047","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10741-023-10303-8","article-title":"Infection as an under-recognized precipitant of acute heart failure: prognostic and therapeutic implications","volume":"28","author":"Bezati","year":"2023","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0048","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S0140-6736(22)00369-5","article-title":"Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial","volume":"399","author":"Ezekowitz","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0049","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1093\/eurheartj\/ehr194","article-title":"Nutrition in cardiovascular disease: salt in hypertension and heart failure","volume":"32","author":"He","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0050","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/CIRCHEARTFAILURE.113.000481","article-title":"Low-sodium DASH diet improves diastolic function and ventricular-arterial coupling in hypertensive heart failure with preserved ejection fraction","volume":"6","author":"Hummel","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0051","article-title":"Sodium restriction in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Colin-Ramirez","year":"2023","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0052","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.nut.2018.02.007","article-title":"Aggressive fluid and sodium restriction in decompensated heart failure with preserved ejection fraction: results from a randomized clinical trial","volume":"54","author":"Machado d'Almeida","year":"2018","journal-title":"Nutrition"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0053","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1161\/CIRCHEARTFAILURE.111.966366","article-title":"Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction","volume":"5","author":"Dunlay","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0054","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1002\/ehf2.13349","article-title":"Left ventricular geometry transition in hypertensive patients with heart failure with preserved ejection fraction","volume":"8","author":"Guan","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0055","doi-asserted-by":"crossref","first-page":"448","DOI":"10.26599\/1671-5411.2023.06.003","article-title":"Nocturnal hypertension and riser pattern are associated with heart failure rehospitalization in patients with heart failure with preserved ejection fraction","volume":"20","author":"Huang","year":"2023","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0056","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1161\/HYPERTENSIONAHA.121.17440","article-title":"Nocturnal hypertension and heart failure: mechanisms, evidence, and new treatments","volume":"78","author":"Kario","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0057","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1253\/circj.CJ-16-0740","article-title":"Riser pattern is a novel predictor of adverse events in heart failure patients with preserved ejection fraction","volume":"81","author":"Komori","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0058","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ehf2.12500","article-title":"Differences in blood pressure riser pattern in patients with acute heart failure with reduced mid-range and preserved ejection fraction","volume":"6","author":"Ueda","year":"2019","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0059","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.rce.2020.11.010","article-title":"Prognostic value of ambulatory blood pressure values in elderly patients with heart failure. Results of the DICUMAP study","volume":"221","author":"Camafort","year":"2021","journal-title":"Rev Clin Esp (Barc)"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0061","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0062","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijcard.2014.08.007","article-title":"Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure","volume":"176","author":"Madamanchi","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0063","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0064","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.15420\/cfr.2021.37","article-title":"Biomarkers in heart failure with preserved ejection fraction","volume":"8","author":"Bayes-Genis","year":"2022","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0066","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.124.072156","article-title":"Evidence-based application of natriuretic peptides in the evaluation of chronic heart failure with preserved ejection fraction in the ambulatory outpatient setting","volume":"151","author":"Reddy","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0067","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC","volume":"25","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0068","article-title":"Diagnostic value of serum concentration of Galectin-3 in patients with heart failure with preserved ejection fraction","volume":"8","author":"Jiang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0069","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004382","article-title":"Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0070","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2174\/0115701611315697241230075727","article-title":"Association of ST2, Galectin-3, and NT- Probnp in elderly hypertensive patients and heart failure with a preserved ejection fraction","volume":"23","author":"Li","year":"2025","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0071","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2018.08.2165","article-title":"Jr. sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T","volume":"72","author":"Emdin","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0072","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2025.1500882","article-title":"Circulating growth differentiation factor-15 concentration and hypertension risk: a dose-response meta-analysis","volume":"12","author":"Yu","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0073","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.431","article-title":"Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction","volume":"18","author":"Chan","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0074","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"Group","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0075","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0076","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with Sacubitril\/Valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0077","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0078","first-page":"1304","article-title":"Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-preserved trial","volume":"46","author":"Bohm","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0079","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.123.065254","article-title":"Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial","volume":"148","author":"Ostrominski","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0080","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0081","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/ejhf.3383","article-title":"Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction","volume":"27","author":"Matsumoto","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2026.04.006_bib0082","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjcard.2026.04.006_bib0083","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.hroo.2022.06.009","article-title":"Rhythm versus rate control for atrial fibrillation in heart failure with preserved ejection fraction","author":"Al-Sadawi","year":"2022","journal-title":"Heart Rhythm O2"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926002316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914926002316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:29:18Z","timestamp":1780403358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914926002316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":83,"alternative-id":["S0002914926002316"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.04.006","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypertensive Heart Disease and HFpEF: What We Have Learned in the Last Decade","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}